Remnant Lipoproteins Are Residual Risk Factor for Future Cardiovascular Events in Patients With Stable Coronary Artery Disease and On-Statin Low-Density Lipoprotein Cholesterol Levels <70 mg/dL-Reference-Cited by-同舟云学术

Remnant Lipoproteins Are Residual Risk Factor for Future Cardiovascular Events in Patients With Stable Coronary Artery Disease and On-Statin Low-Density Lipoprotein Cholesterol Levels <70 mg/dL

Published:2019-05-24 Issue:6 Volume:83 Page:1302-1308
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Fujihara Yuki¹,Nakamura Takamitsu¹,Horikoshi Takeo¹,Obata Jun-ei¹,Fujioka Daisuke¹,Watanabe Yosuke¹,Watanabe Kazuhiro¹,Kugiyama Kiyotaka¹

Affiliation:

1. Department of Internal Medicine II, University of Yamanashi, Faculty of Medicine

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/circj/83/6/83_CJ-19-0047/_pdf

Reference36 articles.

1. 1. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al; ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37: 2999–3058.

2. 2. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol, doi:10.1016/j.jacc.2018.11.003.

3. 3. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 495–504.

4. 4. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195–2207.

5. 5. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713–1722.

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elevated remnant cholesterol improves prognosis of patients with ischemic stroke and malnutrition: a cohort-based study;2024-08-02

2. Current trends in solving the problem of residual cardiovascular risk;Meditsinskiy sovet = Medical Council;2024-05-19

3. Remnant cholesterol and risk of major adverse cardiovascular events: a systematic review and dose–response meta-analysis of cohort studies;Coronary Artery Disease;2024-04-08

4. Comprehensive Assessment of Lipid Markers in Cardiovascular Events Prediction;International Heart Journal;2024

5. Omega-3 Fatty Acids Reduce Remnant-like Lipoprotein Cholesterol and Improve the Ankle–Brachial Index of Hemodialysis Patients with Dyslipidemia: A Pilot Study;Medicina;2023-12-30